Gilder Gagnon Howe & Co. LLC Cuts Position in Natera, Inc. $NTRA

Gilder Gagnon Howe & Co. LLC trimmed its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 11.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,037,390 shares of the medical research company’s stock after selling 129,014 shares during the period. Natera comprises 1.9% of Gilder Gagnon Howe & Co. LLC’s investment portfolio, making the stock its 13th largest position. Gilder Gagnon Howe & Co. LLC’s holdings in Natera were worth $175,257,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Natera by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after acquiring an additional 282,826 shares in the last quarter. JPMorgan Chase & Co. raised its position in Natera by 44.3% in the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after purchasing an additional 3,263,822 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after purchasing an additional 3,795,315 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Natera by 7.0% during the second quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after purchasing an additional 166,768 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in shares of Natera by 20.6% in the second quarter. Franklin Resources Inc. now owns 1,937,647 shares of the medical research company’s stock worth $327,346,000 after buying an additional 330,696 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on NTRA shares. UBS Group increased their price objective on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. BNP Paribas upgraded shares of Natera to a “hold” rating and set a $172.00 target price for the company in a research note on Monday, October 27th. Morgan Stanley lifted their price target on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Piper Sandler upped their price objective on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Finally, Wells Fargo & Company raised their target price on Natera from $175.00 to $190.00 and gave the company an “equal weight” rating in a research note on Friday, November 7th. Fifteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $225.29.

Natera Price Performance

NASDAQ NTRA opened at $231.95 on Friday. The company has a market capitalization of $32.08 billion, a price-to-earnings ratio of -101.29 and a beta of 1.63. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $246.90. The company’s fifty day moving average price is $206.71 and its two-hundred day moving average price is $176.50.

Natera (NASDAQ:NTRA) last released its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.Natera’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.26) EPS. As a group, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Insider Transactions at Natera

In other news, Director Roy D. Baynes sold 7,668 shares of Natera stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $223.08, for a total value of $1,710,577.44. Following the completion of the transaction, the director owned 18,359 shares in the company, valued at approximately $4,095,525.72. This trade represents a 29.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $238.15, for a total value of $714,450.00. Following the sale, the insider directly owned 109,061 shares in the company, valued at approximately $25,972,877.15. This represents a 2.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 312,053 shares of company stock valued at $64,527,735 over the last 90 days. Corporate insiders own 5.63% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.